EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Ojemda (tovorafenib) to treat patients aged 6 months and older with paediatric low-grade glioma (a type of non-cancerous brain tumour).

Ojemda can be used when the tumour has certain changes in the BRAF gene (such as a BRAF fusion, rearrangement or V600 mutation) in patients whose disease has worsened despite previous treatment with one or more systemic medicines.

Paediatric low-grade glioma is the most common brain tumour in children. Although survival is generally high, many patients experience serious long‑term complications affecting vision, movement, learning and overall development, with a significant impact on their quality of life.

Current treatment options include surgery and chemotherapy. While chemotherapy can be effective for some patients, its benefits are often modest and it may cause substantial side effects. In addition, targeted therapy is available only to…